ESR1 and breast carcinoma: Our findings suggest that FGF signaling activation confers resistance to CDK4/6 inhibitors and endocrine therapy and that tasurgratinib shows antitumor activity in combination with endocrine therapy in endocrine therapy-resistant ER+ breast cancer.